| Literature DB >> 35191554 |
Aili Zhang1, Zhi Huang1, Weiwei Tao1, Kui Zhai1, Qiulian Wu2, Jeremy N Rich2, Wenchao Zhou1, Shideng Bao1,3,4.
Abstract
Hypoxia regulates tumor angiogenesis, metabolism, and therapeutic response in malignant cancers including glioblastoma, the most lethal primary brain tumor. The regulation of HIF transcriptional factors by the ubiquitin-proteasome system is critical in the hypoxia response, but hypoxia-inducible deubiquitinases that counteract the ubiquitination remain poorly defined. While the activation of ERK1/2 also plays an important role in hypoxia response, the relationship between ERK1/2 activation and HIF regulation remains elusive. Here, we identified USP33 as essential deubiquitinase that stabilizes HIF-2alpha protein in an ERK1/2-dependent manner to promote hypoxia response in cancer cells. USP33 is preferentially induced in glioma stem cells by hypoxia and interacts with HIF-2alpha, leading to its stabilization through deubiquitination. The activation of ERK1/2 upon hypoxia promoted HIF-2alpha phosphorylation, enhancing its interaction with USP33. Silencing of USP33 disrupted glioma stem cells maintenance, reduced tumor vascularization, and inhibited glioblastoma growth. Our findings highlight USP33 as an essential regulator of hypoxia response in cancer stem cells, indicating a novel potential therapeutic target for brain tumor treatment.Entities:
Keywords: ERK1/2; HIF2α; USP33; deubiquitination; glioma stem cell; hypoxia response
Mesh:
Substances:
Year: 2022 PMID: 35191554 PMCID: PMC8982626 DOI: 10.15252/embj.2021109187
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 11.598